By collaborating with HP, ViewMind can rapidly expand, scale, and secure global distribution for its award-winning breakthrough technology.
FREMONT, CA: The medical device, digital health, and artificial intelligence company ViewMind has announced a new development agreement with HP Inc [HPQ]. ViewMind will use HP's new Reverb G2 Omnicept VR Headset as part of ViewMind's medical device solution to diagnose and monitor cognitive disorders. By collaborating with HP, ViewMind can rapidly expand, scale, and secure global distribution for its award-winning breakthrough technology.
ViewMind has pioneered an affordable, reliable, and accessible digital biomarker for cognitive health and will draw on biosensors within the HP Reverb G2 Omnicept VR Headset to track patients' eye movements in response to visual stimulus delivered through the headset. The biometric data recorded is sent to ViewMind's AI-trained algorithms, which enable the screening, diagnosis, and monitoring of cognitive disorders.
Mark Edwards, CEO ViewMind Inc, "ViewMind are delighted to be collaborating with HP to access the latest innovative HP technologies such as the new HP Reverb G2 Omnicept Edition VR Headset and to ensure ViewMind's award-winning solution can be accessed across global markets."
Alzheimer's disease pathology commences around 20 years before symptoms. By the time a medical diagnosis occurs, a lot of irreversible damage has occurred. Therefore, it is imperative to accurately predict who will convert to Alzheimer's and who will not when mild symptoms are first observed. Another area of importance is treatment impact and the ability to measure outcomes and even screen at the very start of the disease when lifestyle changes and new drug treatments could have the greatest impact on an individual's cognitive health longevity.
Jay Fraser, Head of XR Developer Relations, "ViewMind choosing the HP Omnicept SDK to tackle some of the major challenges in cognitive health diagnosis highlights HP's commitment to solutions that can make a significant global and societal impact in digital health."